Month: September 2022

5 Week Intensive Online Program to Help With Relief From PTSD, Anxiety and Stress for Those Who’ve Experienced Trauma

SCOTTSDALE, Ariz. – September 29, 2022 – (Newswire.com)

Purple Heart Behavioral Health LLC, a premier telepsychology trauma service, announced today an innovative program for PTSD, Anxiety and Stress treatment. The program is a 5-week intensive online program that includes various treatments that have scientific empirical evidence to be effective in treating PTSD, anxiety and stress. 

This innovative new online program offers treatments that have been scientifically shown to be effective in helping people overcome these difficulties. Clinically proven treatments delivered conveniently through telepsychology services bridges rural/urban gaps where resources are sparsely available making quality care accessible to those who need it most regardless of geographical limitations. A compassionate response addressing needs unmet until now.

These therapies include Eye Movement Desensitization Processing (EMDR), Dialectical Behavioral Therapy (DBT), and Cognitive Behavioral Therapy (CBT). Program participants are treated in both individual and group sessions via HIPAA compliant video. Additional psychoeducational videos augment treatment to ensure participants have an opportunity to deeply learn skills and methods taught and used during the program. 

Participants may receive treatment in 31 US states from the comfort of their home, office or hotel with a laptop or tablet. Meeting online prevents obstacles such as driving in traffic, home responsibilities, and confidentiality. Research indicates similar efficacy for face to face and video therapy. 

To date, the Founder of Purple Heart Behavioral Health LLC has guided 100s of people to include military members, Veterans, and civilians through their healing journey. This program will allow more people to gain healing quicker than traditional therapy. Each week builds upon the next with participants attaining new skills, releasing maladaptive behaviors, and gaining functioning all while processing traumatic events that may have caused the symptoms. 

“It is with great happiness and genuine excitement that we announce the launch of Purple Heart’s online intensive program,” said Dr. Angela Kenzslowe, Psychologist and founder of Purple Heart Behavioral Health LLC.  “Our mission is to help people get back in the fight of life faster. This is innovative, on cutting edge, and definitely needed.” 

Says Dr. Kenzslowe: “PTSD and anxiety has become such a crisis in our country, we need to have ways to reach the most people in the quickest way possible. This online program is part of the solution.” 

About:

Purple Heart Behavioral Health LLC was founded by Dr. Angela Kenzslowe in 2016. She is an Army Veteran and was later trained by the Department of Defense to treat trauma, anxiety, stress, and other mental health challenges. The company’s focus is to provide ethical, evidence-based treatment to those who suffer from PTSD, anxiety and stress while enabling patients to be in their most comfortable space such as home or office. 

For more information about Purple Heart Behavioral Health LLC, please visit www.purpleheartbh.com

Contact Information:

Tynan Hilliard

Chief Operating Officer, Purple Heart Behavioral Health LLC

[email protected]

602-529-8120

Angela Kenzslowe

CEO, Purple Heart Behavioral Health LLC

[email protected]

602-529-8120

Press Release Service
by
Newswire.com

Original Source:

Break the Silence; New Intensive Online Program to Help PTSD, Trauma and Anxiety

ALTON, Ill. – September 29, 2022 – (Newswire.com)

Ziemer USA, Inc., a wh…

Hume AI’s platform equips researchers and developers with machine learning tools to better understand vocal and nonverbal communication, improving clinical research, clinical practice, and patient outcomes.

NEW YORK – September 29, 2022 – (Newswire.com)

Northwell Holdings, the for-profit investment arm of Northwell Health, New York State’s largest healthcare provider and private employer, today announced a strategic investment of $3 million in Hume AI, a leading expressive communication research lab and technology company. The investment aims to address the growing demand for scientific tools to understand language and nonverbal expression in the healthcare industry. Hume AI plans to use the funding to refine their advanced machine learning models for use in health applications, including clinical research, patient screening, and accessibility technology.

These models, accessible through Hume AI’s integrated platform, address a significant shortcoming of natural language understanding (NLU) tools, which convert speech into text. NLU tools overlook how the meaning of speech can be transformed dramatically by its tune, rhythm, and timbre, along with nonverbal utterances such as laughs, sighs, and gasps. Such features are particularly important for understanding health conditions such as pain, major depression, and cognitive impairment. With NLU rapidly being integrated into healthcare applications, Hume AI’s platform will enable a more accurate understanding of expressive communication at every step of the patient’s journey, from screening to diagnosis and treatment.

“Technologies that draw upon the latest scientific research to help us better understand not just what people say, but how they say it, have profound potential to benefit patients,” said Rich Mulry, CEO and President of Northwell Holdings. “We already see rising demand for this technology in treatment, clinical research, telehealth applications and more. To promote the careful development of these potentially transformative technologies, we are excited to launch our partnership with Hume AI through an investment that reflects our confidence in Dr. Alan Cowen and his groundbreaking team.”

Hume AI builds its models using new peer-reviewed scientific research and algorithms designed to minimize bias. Previous technologies for understanding nonverbal expression have focused on the expression of six emotions—happiness, sadness, anger, disgust, fear, and surprise—based on established psychological models. Scientific research published in leading journals by Hume AI’s founder and CEO Dr. Alan Cowen, Chief Scientific Advisor Dr. Dacher Keltner, and colleagues has given rise to a more nuanced theory of human expressive behavior. Known as semantic space theory, this work documents how expressions involve complex patterns in language, speech prosody, nonverbal vocalizations like sighs and chuckles, and movement in more than 30 facial muscles. To translate this research into effective machine learning models, Cowen and his team have collected new experimental data from around the world that allow them to characterize the nuances of expressive communication within and across cultures with less bias and more precision.

“In recent years, there have been major scientific advances in our understanding of expressive communication,” Cowen said. “For the first time, we can equip researchers and practitioners in the healthcare space with objective, nuanced, and multidimensional measures of human expression. We are deeply grateful to Northwell Holdings for recognizing the extraordinary potential of this new technology to improve people’s lives and address health inequities. Our partnership will support translational researchers studying how expressive signals relate to mood, mental health, and pain in neuropsychiatric disorders, as well as customers developing new interventions to restore emotional intonation to speech aids, annotate emotional context, and guide empathic behavior.”

For more information on Hume AI, click here.

About Hume AI 

Hume AI is a leading expressive communication research lab and startup with a mission of aligning technology with human well-being. Based on scientific research that reveals a broader spectrum of expressive behavior than previously known, Hume AI offers the world’s most accurate and comprehensive tools for understanding nonverbal expression, including speech prosody, vocalizations like sighs, and facial expressions. Led by founder and CEO Dr. Alan Cowen, an established expert in the field of affective science, Hume AI develops its models using new scientific research that it conducts and regularly publishes in leading journals. The company provides its datasets and models through a unified API platform. Learn more about Hume AI at www.hume.ai and follow us on LinkedIn and Twitter.

About Northwell Holdings

Northwell Holdings (“Holdings”), a fully owned, for-profit subsidiary of Northwell Health, creates value for the health system by investing in early-stage companies, establishing commercial joint ventures, cultivating internally-developed ideas and bringing them to market, and advancing data partnerships that drive innovation in patient care, health diagnostics, and deep technology. We invest in companies that are aligned with Northwell’s mission, promote better health outcomes, improve patient experience, and increase efficiencies in care delivery and services. Through strategic partnerships, Holdings leverages the health system’s robust enterprise data assets to develop AI-enabled solutions that address healthcare inequities. We combine Northwell Health’s clinical and healthcare business expertise and entrepreneurial spirit to bring concepts to life. Northwell Health is New York’s largest healthcare system. To learn more, visit us here and follow us on LinkedIn.

Contact Information:

General Inquires

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Northwell Holdings Announces $3 Million Strategic Investment in Expressive Communication Startup Hume AI to Empower a New Wave of Empathic Healthcare Applications

The noted Atlanta, Georgia urgent care, along with providing the new COVID-19 vaccine, offers need-to-know knowledge about the booster that targets Omicron subvariants, BA.4 and BA.5.

…

William H. Harris, MD, Honored for His Six-Decade-Long Career in Orthopaedics and Transformative Contributions in the Field of Hip Replacements

…

Democratizes access to clinical research in Africa by diversifying participant cohorts and shortening drug development timelines

Clinical Trial …